Evidence map›Paper›PMID 42781284›Full record

ArticleEJHaem2026

Reversible Eltrombopag-Associated Bone Marrow Fibrosis With Hematologic Recovery After Drug Withdrawal in

Kyoko Yoshihara, Ikuo Matsuda, Yasuhito Nannya, Mami Samori, Naru Tomigaki, Saki Takahashi, Chisato Ohe, Satoshi Yoshihara

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kyoko YoshiharaDepartment of Hematology Hyogo Medical University School of Medicine Nishinomiya Japan.
Ikuo MatsudaDepartment of Surgical Pathology Hyogo Medical University School of Medicine Nishinomiya Japan.
Yasuhito NannyaDepartment of Hematology and Oncology The Institute of Medical Science The University of Tokyo Tokyo Japan.
Mami SamoriDepartment of Hematology Hyogo Medical University School of Medicine Nishinomiya Japan.
Naru TomigakiDepartment of Hematology Hyogo Medical University School of Medicine Nishinomiya Japan.
Saki TakahashiDepartment of Hematology Hyogo Medical University School of Medicine Nishinomiya Japan.
Chisato OheDepartment of Surgical Pathology Hyogo Medical University School of Medicine Nishinomiya Japan.
Satoshi YoshiharaDepartment of Hematology Hyogo Medical University School of Medicine Nishinomiya Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypoplastic myelodysplastic syndrome (MDS) often overlaps clinically with aplastic anemia and frequently involves clonal hematopoiesis. Thrombopoietin receptor agonists (TPO-RAs), including eltrombopag, are increasingly used to treat cytopenias in hypoplastic marrow failure syndromes; however, their long-term effects on clonal dynamics and marrow fibrosis remain incompletely defined. We report a case of Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.

Indexed as

ASXL1 mutationbone marrow fibrosiscase reporteltrombopaghypoplastic myelodysplastic syndrome

Identifiers

PMID42781284
PMCPMC13598669

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.